|
1.
|
|
11 p, 1.9 MB |
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
/
Barr, Paul M. (University of Rochester Medical Center, USA) ;
Owen, Carolyn (University of Calgary, Canada) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel) ;
Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA) ;
Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK) ;
Dearden, Claire (The Royal Marsden Hospital, London, UK) ;
Grosicki, Sebastian (Silesian Medical University, Katowice, Poland) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China) ;
Offner, Fritz (Universitair Ziekenhuis Gent, Belgium) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Kipps, Thomas J. (UCSD Moores Cancer Center, San Diego, USA) ;
Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)
What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. [...]
2022 -  10.2217/fon-2022-0898
Future oncology (London, England), Vol. 18 Núm. 37 (january 2022)
|
|
|
2.
|
|
9 p, 996.2 KB |
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2
/
Barr, Paul M. (University of Rochester) ;
Robak, Tadeusz (Medical University of Lodz) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ;
Bartlett, Nancy L. (Washington University School of Medicine) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Devereux, Stephen (Kings College Hospital) ;
Grosicki, Sebastian (School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Li, Jianyong (Jiangsu Province Hospital) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ;
Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ;
James, Danelle (Pharmacyclics. LLC an AbbVie Company) ;
Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510
|
|
|
3.
|
|
11 p, 1.4 MB |
Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
/
Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ;
Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ;
Robak, Tadeusz (Medical University of Lodz) ;
Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Department of Hematology. Rabin Medical Center) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ;
Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ;
Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ;
Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ;
Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ;
Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450
|
|
|
4.
|
|
15 p, 1024.0 KB |
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
/
Zijlstra, Josée M. (Amsterdam UMC) ;
Follows, George (Cambridge University Hospitals NHS Foundation Trust (Regne Unit)) ;
Casasnovas, Rene-Olivier (University Hospital F. Mitterrand) ;
Vermaat, Joost S. P. (Leiden University Medical Center) ;
Kalakonda, Nagesh (University of Liverpool) ;
Choquet, Sylvain (Hôpital Pitié Salpêtrière) ;
Hill, Brian (Taussig Cancer Institute) ;
Thieblemont, Catherine (Saint-Louis Hospital) ;
Cavallo, Federica (University of Torino/AOU) ;
la Cruz, Fatima De (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Kuruvilla, John (Princess Margaret Cancer Centre) ;
Hamad, Nada (University of Notre Dame Australia) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Caimi, Paolo (Case Western Reserve University) ;
Gurion, Ronit (Rabin Medical Center) ;
Warzocha, Krzysztof (Instytut Hematologii I Transfuzjologii) ;
Bakhshi, Sameer (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Schuster, Michael (Stony Brook University Hospital) ;
Egyed, Miklos (Teaching Hospital Mór Kaposi) ;
Offner, Fritz (Ghent University Hospital (Bèlgica)) ;
Vassilakopoulos, Theodoros P. (National and Kapodistrian University of Athens) ;
Samal, Priyanka (Institute of Medical Sciences & SUM Hospital) ;
Ku, Matthew (St Vincent's Hospital (Sydney)) ;
Xu, Jenny (Karyopharm Therapeutics) ;
Corona, Kelly (Karyopharm Therapeutics) ;
Chamoun, Kamal (Karyopharm Therapeutics) ;
Shah, Jatin (Karyopharm Therapeutics) ;
Canales, Miguel (Hospital Universitario La Paz (Madrid)) ;
Maerevoet, Marie (Institut Jules Bordet) ;
Universitat Autònoma de Barcelona
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. [...]
2022 - 10.3390/cancers14030791
Cancers, Vol. 14 (february 2022)
|
|
|
5.
|
|
12 p, 1.8 MB |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
/
Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ;
Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ;
Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ;
Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ;
Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ;
Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ;
Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ;
Kipps, Thomas J. (UCSD Moores Cancer Center) ;
Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
